Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, focused on transplant healthcare solutions, reported Q4 2021 revenue of $79.2 million, a 35% increase year-over-year. Full-year revenue reached $296.4 million, up 54% from 2020. Testing services revenue in Q4 was $68.6 million, while product revenue was $7.7 million. Despite the revenue growth, the company experienced a net loss of $16.2 million in Q4, compared to a loss of $3.5 million in Q4 2020. CareDx aims for 2022 revenues between $330 million and $350 million.
CareDx’s Non-Invasive Blood Tests Revolutionize Organ Health Monitoring
CareDx, Inc. (CDNA) announced that its non-invasive organ transplant surveillance solutions are being utilized in the world's first successful heart xenotransplantation at the University of Maryland Medical Center, performed on January 7, 2022. These innovative tests aid in assessing graft health through gene expression profiling and donor-derived cell-free DNA analysis. CareDx's commitment to transplant patients is highlighted by its established solutions utilized by over 90% of heart transplant centers in the U.S., addressing an urgent organ shortage.
CareDx, Inc. (Nasdaq: CDNA) announced it will release its financial results for Q4 and the full year 2021 on February 24, 2022, after market close. A conference call will follow at 1:30 PM PT / 4:30 PM ET. Interested participants can listen by calling 855-327-6837 in the U.S. or 631-891-4304 internationally, referencing Conference ID: 1001789, or via a live webcast on their investor relations website.
CareDx, Inc. (CDNA) has announced its commitment to raising awareness for organ donation on National Donor Day, February 14. With over 100,000 Americans waiting for organ transplants, the company supports advocacy groups like Donate Life America and the National Kidney Foundation. CEO Reg Seeto emphasized the importance of legislative efforts, including the Living Donor Protection Act, to promote organ donation. The company aims to influence public awareness about organ donations and address critical unmet needs in the transplant community.
CareDx, Inc. (Nasdaq: CDNA) submitted insights from over 250 transplant patients to the Centers for Medicare and Medicaid Services (CMS) regarding the Health and Safety Requirements for transplant programs. This initiative reflects CareDx's commitment to advocating for patient needs. The survey identified key areas for improvement, including increasing organ donor awareness, enhancing patient education, expediting waitlist processes, and providing greater financial assistance. CareDx continues to support legislative policies beneficial to transplant patients, solidifying its role as a leader in transplant care solutions.
CareDx has announced a webinar on February 10, 2022, aimed at educating kidney transplant patients, particularly from underrepresented minorities, about maintaining optimal heart health to prevent cardiovascular complications that can lead to transplant failure. The event, in partnership with MOTTEP, will feature expert panelists discussing critical topics, including organ waitlists and managing post-transplant health. The initiative coincides with Black History Month and Heart Month, emphasizing equity in organ transplantation.
CareDx, Inc. (Nasdaq: CDNA) announced its participation in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 1:00 PM ET and the Raymond James 43rd Annual Institutional Investors Conference on March 7, 2022, at 11:35 PM ET. Interested parties must contact BTIG representatives to access the first event, while the second will be available via a webcast on CareDx's investor relations website. CareDx specializes in healthcare solutions for transplant patients.
CareDx, Inc. (CDNA) has partnered with MOTTEP to enhance minority organ donations and promote disease prevention in underserved communities. This collaboration aims to address health disparities and improve organ transplant outcomes for minority patients, who make up 60% of the U.S. organ transplant waiting list. The partnership will fund educational initiatives to encourage organ registry sign-ups and emphasize the significance of medication adherence post-transplant. CareDx seeks to bridge gaps in healthcare access and patient care for historically underrepresented populations.
CareDx, Inc. (CDNA) announced the publication of results from the ADMIRAL study, demonstrating that its AlloSure® Kidney test effectively detects both clinical and subclinical allograft injuries in kidney transplant patients. The multicenter study, which monitored 1,092 patients, showed a 62% improvement over standard serum creatinine in identifying rejections. AlloSure correlated with a 271% increased risk of donor-specific antibody formation and can predict long-term graft survival. These findings highlight AlloSure's potential to transform transplant care and enhance patient outcomes.
CareDx, Inc. (Nasdaq: CDNA) announced collaborations with three leading biopharmaceutical companies to incorporate its AlloCell surveillance solutions in ongoing CAR T-cell therapy clinical studies. AlloCell serves as a next-generation sequencing tool to monitor the expansion and persistence of allogeneic cell therapies in cancer patients. The potential market for AlloCell in oncology is estimated over $5.5 billion. This initiative reflects CareDx's commitment to advancing cell therapy research and improving patient outcomes.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
